BMS Reports Positive Topline Results From Breyanzi’s Ph3 TRANSFORM Trial in 2L DLBCL vs SoC: Will Breyanzi be the First Approved CAR-T in 2L DLBCL?
On Thursday, June 10, BMS reported positive topline results from Breyanzi’s (CD19 CAR-T) Ph3 TRANSFORM trial in 2L DLBCL (press release). Below, Celltelligence provides insights on how Breyanzi’s potential approval timeline in 2L DLBCL compares with key competitors Kymriah (Novartis) and Yescarta (Gilead / Kite).
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.